DMK · DMK Pharmaceuticals
Acquired Company
Adamis Pharmaceuticals Corporation acquired DMK Pharmaceuticals Corporation on 5/25/2023; DMK merged with and into Merger Sub, with Merger Sub surviving as a wholly owned subsidiary of Adamis.
DMK Pharmaceuticals (NASDAQ: DMK) (previously Adamis Pharma). is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders.The commercially approved products include ZIMHI® (naloxone) and SYMJEPI®. ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue. SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Market Cap
N/A
52 Wk Range
$0.23 - $0.23
Previous Close
$0.23
Open
$0.18
Volume
21,464,152
Day Range
$0.23 - $0.23
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
9.26%
Institutional Own.
2.44%
Qtr Updated
Jun 30th 2024